Humacyte (HUMA) said late Tuesday it priced an underwritten public offering of 25 million shares at $2 per share for expected gross proceeds of $50 million.
The company said the proceeds from the offering, expected to close on Thursday, will support the commercialization of Symvess for vascular trauma, further product development, and general corporate needs.
Humacyte granted the underwriters a 30-day option to purchase an additional about 3.8 million shares.
The company's shares were down more than 23% in premarket activity Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.